Mission Therapeutics appoints Anne Phelan as Senior Vice President, Head of Discovery Research


Drug discovery and development company Mission Therapeutics, has appointed of Anne Phelan as Senior Vice President, Head of Discovery Research.

Mission Therapeutics is focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases.

Phelan has spent more than 20 years in the pharmaceutical industry and brings with her a wealth of drug discovery experience across a number of therapy areas as well as operational knowledge.

She joins Mission from BenevolentAI (formerly Stratified Medical), where she served as VP, Drug Discovery.

Previously, she held a number of senior positions within Pfizer, including COO and Head of Pharmacology at Pfizer Neusentis in Cambridge UK.

Phelan obtained her undergraduate and doctoral degrees in Genetics from the University of Liverpool and carried out her post-doctoral training at the MRC Institute of Virology in Glasgow.

Anker Lundemose, Chief Executive Officer, said:

“Anne will play an invaluable role as we continue to build our internal pipeline and prioritise novel therapeutic programmes for pre-clinical and clinical development.”

“Mission has rapidly earned a reputation as a leading biotech in the Cambridge, UK area,” said Phelan.

“The company’s science and unique DUB platform, with applicability across numerous therapeutic areas, is impressive and has significant commercial potential.”

Sign up for your free email newsletter

“I am looking forward to working alongside Mission’s highly experienced and ambitious leadership team to advance its programmes beyond the discovery phase.”